Article Text

AB0108 Effects of cholic acid and its derivatives in experimental arthritis.
  1. S. Hayer1,
  2. E. Halilbasic2,
  3. B. Niederreiter1,
  4. M. Willburger1,
  5. S. Blüml1,
  6. P. Mandl1,
  7. V. Saferding1,
  8. J. Smolen1,
  9. M. Trauner2,
  10. K. Redlich1
  1. 1Internal Medicine III, Division of Rheumatology
  2. 2Internal Medicine III, Division of Gasteroenterology, MEDICAL UNIVERSITY OF VIENNA, Vienna, Austria


Background Bile acids play an important role in cholesterol metabolism and act as intestinal detergents for digestion and absorption of fats and fat-soluble vitamins. Disruption of bile flow causes cholestatic liver diseases. Derivatives of cholic acid (CA) such as nor-ursodeoxycholic acid (norUDCA) are promising therapeutic agents in the treatment of cholangiopathies. Previous studies also demonstrated anti-inflammatory and anti-fibrotic properties of norUDCA in experimental sclerosing cholestasis.

Objectives To investigate the anti-inflammatory potential of CA and its derivatives ursodeoxycholic acid (UDCA) and nor-UDCA in Collagen-induced arthritis (CIA), an animal model for inflammatory, erosive arthritis.

Methods Mice were prophylactically treated with CA, UDCA or nor-UDCA enriched diet pellets (5mg/kg diet) or standard diet pellets (Placebo) ad libitum starting 1 week before the first immunisation with collagen. Animals were weekly assessed for clinical signs of arthritis, body weight and food consumption during the experimental period. After 10 weeks of treatment hind paws, liver, sera and lymph nodes were isolated for further analysis. Sera were investigated for anti-collagen antibodies, cytokine responses and liver parameters. Paraffin-sections of hind paws were examined for histopathological changes in synovial inflammation, subchondral bone erosion, cartilage damage and osteophyte formation. Cell populations within synovial pannus were identified by immunhistochemical stainings.

Results Uptake of CA, UDCA and norUDCA was confirmed by serum analysis. Prophylactic treatment of CIA mice with UDCA significantly prevented disease incidence, however severity of arthritis developed like in Placebo-treated animals. In contrast, treatment with norUDCA could not prevent incidence of CIA and showed a similar course of clinical signs of arthritis. Remarkably, treatment with CA led to a marked increase in disease incidence and severity compared to Placebo treated animals. Histological analysis of hind paws revealed an increase in synovial inflammation, bone erosion and cartilage damage in the CA treated animals compared to the Placebo group. No changes in joint pathology were observed in the UDCA or norUDCA treated group. Despite differences in absolute numbers of infiltrating cells, immunhistochemical staining demonstrated no markedly changes in the distribution of neutrophils, macrophages, T- and B-lymphocytes within inflammatory synovial tissue. Similar amounts of total anti-collagen IgG and its subtypes IgG2 and IgG2c were found in all treatment groups. Moreover, FACS analysis revealed similar amounts of T-cells, B-cells, dendritic cells and macrophages and similar expression in costimulatory molecules on antigen-presenting cells. In contrast, serum analyses revealed a trend toward increased IL-6 levels suggesting that CA exacerbates IL-6 levels driving disease onset and severity in CIA model.

Conclusions Bile acid derivatives UDCA and norUDCA could not modulate collagen-induced arthritis. In contrast, cholic acid (CA) exacerbated the incidence and severity of inflammatory, erosive arthritis in this model. Thus, promising anti-inflammatory and anti-fibrotic agents for cholangiopathies have therefore no beneficial effects in an experimental arthritis model.

Disclosure of Interest None Declared

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.